{"id":"ocrelizumab-cinnagen-iran","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"},{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Neurological disorders"}]},"_chembl":{"chemblId":"CHEMBL2108041","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to CD20, ocrelizumab induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, leading to the depletion of B cells. This mechanism is thought to be beneficial in treating autoimmune diseases such as multiple sclerosis and non-Hodgkin's lymphoma.","oneSentence":"Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:48.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"},{"name":"Primary progressive multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT04966338","phase":"PHASE3","title":"Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2019-08-19","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xacrel®"],"phase":"phase_3","status":"active","brandName":"Ocrelizumab (CinnaGen, Iran)","genericName":"Ocrelizumab (CinnaGen, Iran)","companyName":"Cinnagen","companyId":"cinnagen","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells. Used for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}